Trade Secret vs Patent: How to Protect Technology Before Disclosure
A company develops technology that gives it an advantage. Part of that advantage may be visible once the product reaches customers. Another part may sit inside the factory, cloud infrastructure, source code, control system, dataset, manufacturing process, deployment procedure, or operating model. The business may describe the decision as trade secret vs patent, but the real choice is more precise: which parts should be disclosed in exchange for patent rights, and which parts can realistically remain confidential?
That choice matters because patent protection and trade secret protection solve different problems. A patent can create an exclusionary right even against a competitor that independently develops the same invention. A trade secret can protect valuable internal information for as long as secrecy is preserved, but it does not stop lawful reverse engineering or independent development. The two systems can work together, but they cannot protect the same disclosed information in the same way.
For founders, executives, inventors, technical teams, and investors, the decision should be made before disclosure, commercialization, vendor sharing, investor diligence, publication, or launch narrows the options. Once a patent application publishes, the disclosed information is no longer secret. Once a product can be inspected and reverse engineered, trade-secret-only protection may become fragile. Once a secret process is commercially exploited, future patent rights may be affected even if customers never learn the process.
The strongest IP strategy therefore starts by separating the technology into layers. Patent the parts competitors can see, reproduce, or independently develop when meaningful claim scope is available. Protect the hidden implementation knowledge as trade secrets when secrecy controls can survive real business operations. The USPTO describes trade-secret protection as complementary to patent protection, which is the right way to frame the decision: trade secret vs patent is often a question of allocation, not replacement.
A Patent Protects Against Independent Development
A patent protects against a risk that trade-secret law generally does not reach. Under 35 U.S.C. § 154, a patent gives the owner the right to exclude others from making, using, offering to sell, selling, or importing the patented invention in the United States. For a utility patent, the term generally runs 20 years from the filing date of the earliest nonprovisional U.S. application from which benefit is claimed, subject to patent term adjustment, patent term extension, terminal disclaimers, and timely maintenance fees. A provisional application does not start that clock and is not published on its own. A provisional application therefore preserves an early priority date for up to twelve months while the company continues to evaluate whether disclosure is worth the exclusionary right.
That exclusionary right matters because patent infringement does not usually depend on proving that the competitor copied the patent owner. If a competitor independently builds technology that falls within every required limitation of a valid patent claim, independent development alone will not defeat infringement. For inventions that are likely to be recreated by others, that can be a decisive advantage.
Even so, a patent is only as strong as its claims. A long technical disclosure may describe impressive engineering, but enforcement turns on the claim language. If the claims are broad enough to cover commercially meaningful alternatives and defensible against prior art, the patent may create real leverage. If the claims are narrow and easy to design around, disclosure may cost more than the protection is worth.
This is why the patent question should not stop at whether the invention is patentable. The better question is whether the company can obtain claim scope that justifies public disclosure, prosecution cost, maintenance, and future enforcement.
A Trade Secret Protects Confidential Value
Trade-secret protection begins with secrecy, value, and reasonable measures. Under the Defend Trade Secrets Act, protectable trade-secret information can include business, financial, scientific, technical, economic, or engineering information, including formulas, designs, methods, techniques, processes, procedures, programs, and code. The owner must take reasonable measures to keep the information secret, and the information must derive actual or potential economic value from not being generally known or readily ascertainable through proper means.
Trade-secret rights also arise under state law. Nearly every state has adopted a version of the Uniform Trade Secrets Act, and New York continues to apply common-law principles, so most disputes involve parallel federal and state theories with differing definitions, remedies, and preemption rules. Under the DTSA, available relief can include injunctive relief, actual damages, unjust enrichment, a reasonable royalty, exemplary damages of up to twice the compensatory award for willful and malicious misappropriation, attorney fees, and in extraordinary circumstances an ex parte seizure order. The DTSA also limits injunctions that would restrain a person from entering an employment relationship, and it requires suit within three years after the misappropriation is discovered or should have been discovered through reasonable diligence. Willful theft of trade secrets can additionally carry criminal exposure under 18 U.S.C. §§ 1831 and 1832.
That definition reaches many assets a patent may never describe well. Source code, manufacturing recipes, engineering tolerances, production settings, datasets, testing protocols, supplier specifications, pricing methods, model weights, calibration procedures, quality-control processes, deployment procedures, customer information, and internal architecture may all qualify if the facts support secrecy and value.
The limits are just as important. Trade-secret law protects against misappropriation, such as improper acquisition, use, or disclosure. It does not give the owner exclusive rights against the world. The DTSA excludes reverse engineering, independent derivation, and other lawful means of acquisition from “improper means.” As a result, trade-secret protection depends heavily on whether competitors can lawfully discover the information and whether the company can prove it treated the information as secret.
That is the first major divide in the patent vs trade secret analysis. If the advantage is hidden and can remain hidden, trade-secret protection may fit. If the advantage becomes visible through product use, testing, sale, or inspection, trade-secret-only protection may be too fragile.
Disclosure Is the First Strategic Divide
Disclosure changes everything. A patent strategy requires enough disclosure to satisfy patent law. A trade-secret strategy requires the opposite: controlled secrecy. The company needs to know which path it is taking before public communications, investor decks, product demos, customer pilots, technical papers, GitHub repositories, conference presentations, or sales activity create avoidable risk.
Patent law exchanges disclosure for exclusion. Under 35 U.S.C. § 112, the patent specification must describe the invention and explain how to make and use it in terms sufficient for a skilled person. The application must also conclude with claims that particularly point out and distinctly claim the invention.
Section 112(a) also requires the specification to set forth the best mode contemplated by the inventor of carrying out the invention. A company cannot claim an invention while deliberately withholding the best version of that claimed invention from the specification. The America Invents Act removed failure to disclose the best mode as a basis for invalidity or unenforceability under 35 U.S.C. § 282(b)(3)(A), but the disclosure duty itself remains, and concealment can still surface as an inequitable-conduct or credibility problem in litigation. The workable line is scope, not concealment: what falls outside the claims can remain confidential, while the best mode of what is claimed must be disclosed.
That does not mean every practical refinement must be disclosed in every patent application. The application must support the claimed invention. Separate implementation know-how, process tuning, datasets, operating thresholds, supplier details, calibration methods, or deployment practices may remain trade-secret candidates if they are not required for the claims and are not otherwise made public.
Accordingly, the disclosure plan should be drafted before filing, not after publication. Counsel and technical teams should identify what the patent must teach, what it should claim, and what confidential know-how can remain outside the public record. Without that separation, the company may either undercut patent validity or accidentally publish the very advantage it intended to keep secret.
Patent Publication Can End Trade Secret Protection
Most nonprovisional U.S. patent applications are published around 18 months after the earliest filing date for which benefit is sought. Section 122(b) sets that framework and allows a nonpublication request only where the invention has not been and will not be the subject of an application filed in a foreign country or under a multilateral agreement that requires publication. That election carries a trap. If the applicant later files abroad, it must notify the USPTO within 45 days, and failure to give that notice results in abandonment of the U.S. application. A nonpublication request should therefore be treated as an international filing decision, not merely a secrecy preference.
Once an application publishes, the disclosed information becomes public. The company cannot later treat that same disclosed teaching as a trade secret. It may still have trade secrets around separate undisclosed know-how, but those secrets must be identifiable and genuinely distinct from what the patent publication taught.
The Federal Circuit’s 2025 decision in Coda Development v. Goodyear illustrates the risk. Coda claimed trade-secret protection for information relating to self-inflating tire technology, but the court found that one asserted secret had already been disclosed through Coda’s own PCT publication and a later technical article. To the extent Coda relied on separate undisclosed know-how, the court found the identification insufficiently specific.
The practical lesson is direct. Patent publication destroys secrecy in what it teaches. It does not destroy every related item of confidential know-how by default. However, the company must be able to define what remains secret with precision. Vague references to experience, design knowledge, or “know-how” may not survive scrutiny.
Commercial Use Can Affect Future Patent Rights
A company may assume it can keep a process secret, commercialize products made through that process, and later file for patent protection if the market responds well. That assumption can be dangerous.
Section 102 identifies patentability bars involving prior patenting, printed publication, public use, sale, or other public availability, subject to statutory exceptions. The issue becomes especially important when a company commercially exploits a secret process before filing.
Celanese International Corp. v. ITC, decided by the Federal Circuit in 2024, is the central warning. Celanese used a confidential process to manufacture acesulfame potassium and sold product made by that process more than one year before its patent filings. The court held that those commercial sales triggered the on-sale bar under 35 U.S.C. § 102(a)(1) and precluded later patent claims covering the process, rejecting the argument that the America Invents Act eliminated that principle for secret processes. The sale of the product placed the process on sale even though the process itself stayed confidential.
For business planning, the lesson is simple. Secret commercialization can still create patent consequences. Customers may never learn the process, yet the company’s own commercial use may still affect later patent rights. If the technology may be worth patenting, the timing review should happen before sales, offers, public use, or commercial deployment.
That timing problem often has a low-cost solution. Filing a provisional application before the first offer for sale, sale, public use, or commercial deployment preserves patent options without publishing anything and without starting the patent term. The company then has twelve months of market feedback before it has to commit to a nonprovisional filing, foreign filings, or abandonment in favor of secrecy. Where the process is the commercial advantage, that filing should be evaluated before the first invoice, not after the product succeeds.
Timing carries a further consequence outside the United States. U.S. law provides a limited one-year grace period for certain disclosures made by the inventor or obtained from the inventor, but many other jurisdictions apply an absolute-novelty standard under which any public disclosure before filing can forfeit patent rights in that country. A conference presentation, published paper, product demonstration, trade-show exhibit, public repository, or open sales activity may therefore preserve U.S. options while extinguishing European and other foreign options on the same day. Filing before the first public disclosure protects both. A first filing also starts a twelve-month priority window under the Paris Convention that allows foreign or international filings to claim the original filing date. Where the technology was made in the United States, a foreign filing license should be confirmed before filing abroad, because filing outside the United States without the required license can jeopardize the corresponding U.S. patent.
Trade-secret protection abroad is likewise uneven. The European Union harmonized core standards through its trade secrets directive, and many other countries protect confidential information through unfair-competition law, contract law, labor law, or criminal statutes rather than a dedicated trade-secret regime. Definitions, available remedies, injunctive practice, evidentiary rules, and the practical ability to obtain discovery or preserve confidentiality during litigation vary considerably. A company operating across borders should therefore treat contracts, access controls, and internal segmentation as the protection layer it can actually rely on, and should evaluate where manufacturing partners, contractors, and cloud infrastructure are located before assuming a secret will be enforceable everywhere it travels.
Reverse Engineering Changes the Trade Secret Analysis
Trade-secret protection is strongest when lawful reverse engineering is difficult or impractical. If a competitor can buy the product, inspect it, test it, disassemble it, analyze the composition, observe the workflow, or infer the method through lawful means, the trade-secret position weakens.
That does not mean every sold product destroys every trade secret connected to it. The question is whether the particular information claimed as secret is actually readily ascertainable through proper means. A product may be public while certain tolerances, source code, backend systems, process settings, manufacturing methods, or operating parameters remain hidden.
This distinction is especially important for hardware, devices, chemicals, and software-enabled products. A physical mechanism may be visible after teardown. A chemical composition may be analyzed. A user-facing workflow may be observed. Meanwhile, a factory process, calibration routine, internal algorithm, quality-control method, dataset, or deployment configuration may remain unavailable to customers and competitors.
Therefore, the company should map the product from the outside in. Identify what customers see, what competitors can test, what vendors receive, what remains server-side, and what only internal personnel know. Patent protection becomes more attractive for visible or reverse-engineerable features. Trade-secret protection becomes more attractive for hidden knowledge that can remain confidential under real operating conditions.
Independent Development Creates a Different Risk
Trade-secret law does not stop a competitor from independently developing the same technology. That is one of the sharpest differences between trade secrets and patents. If another team reaches the same solution without improper acquisition, use, or disclosure of your confidential information, the trade-secret owner may have no claim.
That risk matters most in crowded technical fields. AI infrastructure, semiconductors, data-center cooling, medical devices, robotics, energy systems, industrial automation, and software architecture often involve multiple teams trying to solve the same technical problems. Secrecy can preserve internal knowledge, but it does not create an exclusionary right against lawful independent invention.
Prior commercial use may provide a limited defense in some patent cases, but it should not be treated as a substitute for patent protection. Section 273 creates a defense for qualifying prior commercial users, subject to detailed requirements. The commercial use generally must have occurred in the United States at least one year before the earlier of the patent’s effective filing date or the date the claimed invention was publicly disclosed under an applicable exception. The defense requires clear and convincing evidence, is personal to the qualifying user, carries transfer and site restrictions, is unavailable where the use was abandoned, and does not create a broad license to practice every related claim. A defense asserted without a reasonable basis can expose the asserting party to attorney fees.
So the decision is strategic. If the technology is likely to be independently developed and broad patent claims are available, patent protection may be worth the disclosure. If independent development is unlikely because the advantage depends on proprietary data, accumulated process knowledge, specialized operations, or confidential infrastructure, trade-secret protection may carry more value.
Reasonable Measures Decide Whether the Secret Survives
A trade secret survives only if the business treats the information like a secret. The DTSA does not require perfect security, but it does require reasonable measures under the circumstances. What is reasonable depends on the value of the information, company size, access needs, industry practice, technical risk, third-party exposure, cost, practicality, and expected duration of secrecy.
A startup and a semiconductor manufacturer will not have identical control environments. Still, “everyone knew it was confidential” is a weak record. The company should be able to identify the secret, where it is stored, who owns it internally, who has access, which agreements govern it, what technical controls apply, and why it has value because it is not generally known.
That identification becomes critical in litigation. Courts regularly reject vague trade-secret descriptions that sound like broad technical experience rather than specific confidential information. A company should be able to distinguish the asserted secret from public knowledge, employee skill, general industry practice, and information disclosed in patents or publications.
The operating controls should match the asset. Confidentiality agreements, invention-assignment agreements, role-based access, segmented repositories, restricted downloads, encrypted storage, multi-factor authentication, limited vendor access, confidentiality markings, employee training, and structured offboarding can all help. The issue is not whether the company can recite a policy. The issue is whether the daily workflow supports secrecy.
Employees Contractors and Vendors Are the Real Leak Points
Most trade secrets leave through ordinary business relationships, not dramatic intrusions. Engineers need access. Manufacturers receive specifications. Contractors work inside repositories. Investors review diligence materials. Customers may receive technical documentation. Acquirers examine architecture. Research partners exchange information. Each relationship can either preserve or weaken trade-secret protection.
Employees create the most common exposure. Employment agreements should address confidentiality, invention ownership, return of materials, company systems, and post-employment obligations. Offboarding should include access revocation, device return, credential termination, repository removal, review of unusual downloads, confidentiality reminders, and return or destruction certification where appropriate.
Contractors require separate attention because payment does not automatically solve ownership. Contractor agreements should address ownership of inventions, patent rights, source code, documentation, derivative improvements, background IP, newly developed IP, confidential information, and assignment obligations. Without that language, the company may find that its supposed trade-secret system depends on code, deliverables, or documentation it does not clearly own.
Vendors and collaborators need precise boundaries. Agreements should define the confidential information, permitted purpose, personnel access, subcontractor limits, information-security obligations, incident notice, return and deletion, deliverable ownership, improvement ownership, and audit or verification rights where appropriate. In university or research collaborations, publication expectations should be addressed early because publication can conflict directly with secrecy.
The DTSA also contains a whistleblower-immunity notice requirement. Section 1833(b) provides immunity for certain confidential disclosures of trade secrets to government officials or attorneys for the purpose of reporting or investigating a suspected legal violation, and for trade secrets disclosed in a complaint or other document filed under seal. Employers must give notice of this immunity in any agreement with an employee that governs the use of trade secrets or other confidential information, and for this provision “employee” includes contractors and consultants. An employer that fails to give the notice cannot recover exemplary damages or attorney fees under the DTSA against that employee. The notice may be satisfied by cross-reference to a policy document that sets out the employer’s reporting procedures.
Patent and Trade Secret Disputes Require Different Evidence
Patent and trade-secret disputes are not simply different versions of the same case. They ask different proof questions, so the protection strategy should anticipate the future evidentiary record.
In a patent case, the owner generally needs to show that the accused product or process falls within the asserted patent claims. The dispute may involve claim construction, technical experts, product testing, source code, prior art, invalidity defenses, damages, and sometimes Patent Trial and Appeal Board challenges. Independent development usually does not answer direct infringement.
In a trade-secret case, the first question is different: what exactly was the secret? After that, the owner must prove secrecy, economic value from secrecy, reasonable measures, misappropriation, and use or disclosure. The defendant may argue independent development, lawful reverse engineering, public availability, insufficient identification, or inadequate protective measures.
That difference affects recordkeeping now. Patent portfolios need invention records, assignments, claim strategy, prosecution history, prior-art analysis, and product mapping. Trade-secret portfolios need inventories, access logs, confidentiality agreements, repository controls, vendor records, offboarding evidence, disclosure histories, and proof that the information remained secret.
The practical comparison is direct. Patent litigation asks whether the accused technology falls within the legal scope of the claims. Trade-secret litigation asks what confidential information existed, how it was protected, how the defendant obtained it, and what the defendant did with it.
Hybrid IP Protection May Be the Strongest Strategy
The best trade secret vs patent answer may be both, but only if the business separates the technology carefully. Hybrid protection does not mean patenting an invention while pretending the patented disclosure remains secret. Once information is publicly disclosed in a patent application, that information is no longer a trade secret. Hybrid strategy means allocating different layers of the technology to different forms of protection.
A data-center cooling system may contain patentable hardware and secret control logic. The patent candidates may include fluid-delivery architecture, heat-exchanger arrangements, manifold geometry, sensor configuration, and rack integration. The trade-secret candidates may include control thresholds, calibration routines, predictive-maintenance models, operating datasets, installation tolerances, and failure-response logic.
An AI platform may divide the same way. Patent candidates may include technically specific computing architectures, distributed inference mechanisms, memory-management improvements, retrieval systems, latency-reduction methods, or hardware-software integration. Trade-secret candidates may include training datasets, model weights, evaluation sets, ranking parameters, fine-tuning methods, deployment configuration, and guardrail tuning.
The disclosure boundary should be drawn deliberately. Counsel should not omit information required to support the patent claims. Instead, the company should decide which technical concept justifies patent disclosure and which separate implementation knowledge can remain confidential. That is how a hybrid IP strategy preserves exclusionary rights and secrecy without confusing the two.
The following comparison summarizes how the two systems differ across the factors that usually drive the allocation decision.
Patent vs. Trade Secret Protection
The following comparison summarizes how the two systems differ across the factors that usually drive the allocation decision.
| Factor | Patent | Trade Secret |
|---|---|---|
| How the right arises | Federal grant issued after examination by the USPTO | No filing or registration; arises from secrecy in fact under the DTSA and state law |
| Duration | Generally 20 years from the earliest nonprovisional filing date, subject to adjustment, extension, terminal disclaimers, and maintenance fees | Indefinite while secrecy and value persist; ends immediately upon public disclosure |
| Disclosure required | Enabling written description, plus the best mode of the claimed invention; most applications publish at about 18 months | None; disclosure destroys the right |
| Independent development by a competitor | Not a defense to infringement | Complete defense |
| Lawful reverse engineering | Not a defense to infringement | Excluded from improper means; defeats the claim as to what is ascertained |
| Core proof at trial | That the accused product or process falls within the asserted claims | Identification of the secret with specificity, secrecy, value from secrecy, reasonable measures, and misappropriation |
| Principal vulnerability | Invalidity over prior art, eligibility challenges, post-grant review, design-arounds | Disclosure, insufficient identification, inadequate measures, employee and vendor leakage |
| Cost profile | Front-loaded prosecution cost, maintenance fees, separate foreign filings | Ongoing security controls, contracts, access management, monitoring, and offboarding |
| Timing sensitivity | Sales, offers, and public use can bar patenting; file before commercialization | No filing deadline, but secrecy must be maintained continuously from the outset |
| Remedies | Injunctive relief, damages no less than a reasonable royalty, up to treble damages for willfulness, fees in exceptional cases | Injunctive relief, actual damages, unjust enrichment, reasonable royalty, up to double exemplary damages, fees, and in extraordinary circumstances ex parte seizure |
| Time limits on suit | No statute of limitations to file; damages recovery limited to the six years before the complaint | Suit within three years after the misappropriation is discovered or should have been discovered |
| Territorial reach | Country by country; rights must be obtained in each jurisdiction | Protectable wherever secrecy is maintained, but enforcement standards vary widely by country |
| Diligence and licensing posture | Publicly inspectable asset; ownership, term, and scope are verifiable | Requires an internal inventory, agreements, access records, and disclosure history to be credible |
AI Data Centers and Technical Systems Often Need Both
AI companies should avoid treating “the model” as one asset. Modern AI systems contain separate components, and each component may require a different protection strategy. Model architecture, inference optimization, hardware integration, and distributed computing improvements may deserve patent review where they represent concrete technical improvements. Model weights, datasets, evaluation methods, prompts, ranking logic, and deployment configuration may be better suited to trade-secret protection if access is tightly controlled.
The USPTO’s November 2025 revised inventorship guidance for AI-assisted inventions clarifies that the same legal standard for determining inventorship applies whether or not AI systems were used in the inventive process. The USPTO also rescinded its February 2024 guidance and reaffirmed that only natural persons can be inventors.
Data-center technology presents a similar split. Cooling hardware, heat-exchanger architecture, rack integration, sensors, power systems, and device configurations may be visible enough to justify patent analysis. Workload orchestration, operating thresholds, maintenance analytics, deployment procedures, telemetry, network configuration, and internal control logic may remain confidential if the business controls access.
These industries show why the choice is rarely one-dimensional. A company may need patents to cover observable architecture and trade secrets to protect operational advantage. The legal strategy should match the technical architecture rather than forcing all value into one category.
Investors Need Proof That the IP Moat Is Real
Patent assets and trade-secret assets create different diligence questions. A patent is visible. An investor can review ownership, claims, filing history, assignments, maintenance status, foreign counterparts, prosecution history, remaining term, litigation, and post-grant challenges. That does not make the patent automatically valuable, but it makes the legal asset easier to inspect.
Trade secrets are intentionally invisible, so diligence focuses on the system protecting them. Investors and acquirers need to know what the secrets are, who owns them, who has access, where they are stored, why they have value, how they are protected, and whether they have been disclosed.
A trade-secret-heavy company should maintain an internal inventory. That inventory should identify the secret without revealing it unnecessarily, connect it to business value, identify the access group, list controlling agreements, and note any disclosure history. If management says everything is proprietary but cannot identify the specific confidential assets, diligence will suffer.
Ownership is just as important. Employees should have invention-assignment agreements. Contractors should assign relevant code, documentation, inventions, and deliverables. Vendor and joint-development agreements should address improvements and background IP. If the company cannot prove ownership and control, the claimed moat may look more like an operational assumption than an asset.
How to Choose Between Trade Secret and Patent Protection
The trade secret vs patent decision should move through a sequence. Start with visibility. If competitors can inspect, measure, test, or reverse engineer the advantage from a lawfully obtained product, patent protection becomes more attractive. If the advantage remains inside the factory, server, model, dataset, or internal process, secrecy may remain viable.
Then consider commercial lifespan. A short-lived implementation may be better protected through secrecy if patent enforcement will not matter before the technology changes. A durable device architecture or manufacturing system may justify patent protection if the claims can cover meaningful commercial value.
Patentability comes next. Evaluate subject-matter eligibility, novelty, nonobviousness, enablement, claim breadth, and design-around options. A patent that can only issue with narrow claims may not justify disclosure. At the same time, a technology that cannot be kept secret may need patent analysis even if prosecution will be difficult.
Finally, test whether secrecy can survive the business model. How many employees, contractors, suppliers, customers, investors, partners, and acquirers need access? Are controls real or aspirational? What happens if the secret leaks? Does licensing require a publicly defined right? Can the technology be divided into patentable architecture and confidential implementation knowledge?
The answer may be patent-led, trade-secret-led, or hybrid. A patent-led strategy fits observable, independently reproducible, sufficiently patentable technology where exclusion justifies disclosure. A trade-secret-led strategy fits valuable information that can remain genuinely inaccessible and retain value under realistic controls. A hybrid strategy fits technology with both observable architecture and hidden implementation knowledge.
Trade Secret vs Patent Is an IP Architecture Decision
The final decision should not turn on which protection period sounds longer. It should turn on architecture. What should be disclosed in exchange for an exclusionary right? What can realistically remain confidential? Which contracts, access controls, filing decisions, and diligence records preserve the most valuable combination?
A medical device can contain patented structure and confidential manufacturing specifications. A chemical product can be patented while production efficiencies remain secret, although commercialization timing must be reviewed before patent rights are compromised. A software platform can include patentable technical improvements while preserving source code, deployment logic, data, and operational parameters as secrets.
Trade secret vs patent is therefore a commercial architecture decision. The right answer is often not one system replacing the other. It is a disciplined allocation of protection across the parts of the technology competitors can see, the parts they can lawfully recreate, the parts they may independently develop, and the parts your business can still keep confidential.
In particular, Kevin specializes in preparing and executing strategies for obtaining domestic and international patent protection for clients’ inventions.In addition to his experience preparing and prosecuting patent applications, Kevin has experience with post-grant proceedings before the U.S. Patent and Trademark Office.Kevin also has experience working with inventors to help determine patentability and points of novelty of their inventions.
- Trade Secret vs Patent: How to Protect Technology Before Disclosure - September 23, 2026
- Your Provisional Patent Application Is Only as Strong as What You Disclosed - September 16, 2026
- Patent Protection Before Filing - August 5, 2026
